ctDNA NGS Panel for Liquid Biopsy Research

Introduction

Circulating tumor DNA (ctDNA) analysis using next-generation sequencing (NGS) has emerged as a promising approach for noninvasive cancer detection and monitoring. ctDNA refers to small fragments of DNA that are released into the bloodstream by tumor cells, offering a window into the genetic information of the tumor without the need for invasive tissue biopsies.

Unlike traditional serum-based protein biomarkers, ctDNA analysis provides valuable information about the specific genetic alterations present in the tumor. This is important because driver mutations, which are key genetic changes that promote cancer development and progression, can be identified through somatic variant detection using ctDNA.

Circulating tumor DNA (ctDNA) is single- or double-stranded DNA released into the bloodstream by tumor cells and therefore contains mutations in the original tumor as well as biomarkers of additional diagnostic and prognostic potential. Based on our cutting-edge target enrichment and next-generation sequencing (NGS) technology platforms, we are investigating the use of liquid biopsies to detect ctDNA in tumors. CD Genomics offers ctDNA NGS analysis solutions to detect DNA fragments in cancers for invasive tissue biopsies.

Our ctDNA panel can evaluate 16 genes for colorectal cancer, 27 genes for breast cancer, and 28 genes for lung cancer. Customers can choose the target genes that suit your purpose from the gene list.

ctDNA Panel for Colorectal Cancer	Target Enrichment Method: Hybridization capture. Market-leading Sensitivity & Specificity: SNV and Indel with over 97% sensitivity at 0.5% VAF, and 98% specificity for SNV and Indel. Sequencing Platforms: Next-generation Sequencing devices, including Illumina and MGI Sequencing platforms. Customization: We provide Colorectal Cancer Panel Sequencing Services for customed panel design and sequencing requirements.
ctDNA Panel for Colorectal Cancer	16 Genes: APC BRAF EGFR ERBB2 ERBB3 FGFR1 HRAS IRS1 KRAS MET NRAS PDGFRB PIK3CA PTEN TP53
ctDNA Panel for Breast Cancer	Target Enrichment Method: Hybridization capture. Market-leading Sensitivity & Specificity: SNV and Indel with over 94% sensitivity at 0.5% VAF, and 96% specificity for SNV and Indel. Sequencing Platforms: Illumina and MGI Sequencing platforms. Customization: We provide Breast Cancer Panel Sequencing Services for customed panel design and sequencing requirements.
ctDNA Panel for Breast Cancer	27 Genes: AKT1 APC AR BRCA1 BRCA2 CCND1 CDH1 EGFR ERBB2 ESR1 FGFR1 FGFR2 GATA3 IGF1R KIT KRAS MAP2K4 MAP3K1 MDM2 MYC NF1 PIK3CA PIK3R1 PTEN RB1 TOP2A TP53
ctDNA Panel for Lung Cancer	Target Enrichment Method: Hybridization capture. Market-leading Sensitivity & Specificity: SNV and Indel with 100% sensitivity at 0.5% VAF, and 99.9% specificity for SNV and Indel. Sequencing Platforms: Illumina and MGI Sequencing platforms. Customization: We provide Lung Cancer Panel Sequencing Services for custom panel design and sequencing requirements.
ctDNA Panel for Lung Cancer	28 Genes AKT1 ALK ARAF ARID1A BRAF CBL CDKN2A EGFR ERBB2 HRAS KEAP1 KRAS MAP2K1 MET MTOR NF1 NRAS NTRK1 NTRK2 PIK3CA PTEN RB1 RIT1 ROS1 SETD2 STK11 TP53 U2AF
CDAMP® ctDNA 50 Panel	Target Enrichment Method: Multiplex PCR amplicon. Covers a total of 50 genes associated with cancers of the non-small-cell lung cancer, breast, ovary, gastric and colorectal, etc. Sensitivity & Specificity: Low-frequency variants below 0.1% allele frequency can be detected. Sequencing Platform: Illumina
Bioinformatics Service	Primary and secondary data analysis with the current frontiers of disease genomics and pharmacogenomics to support optimized analysis recommendations. Learn more.

The ctDNA panel offers but not limited to:

The panel is an NGS assay that can be used for ctDNA liquid biopsies for colorectal, breast and lung cancers and other diseases.
Stringent quality control throughout the pipeline workflow ensures accurate and reproducible sequencing.
Provides the sensitivity and specificity required to detect low levels of ctDNA in the blood.
In addition to targeting individual genes or subsets of genes, NGS can identify genome-wide tumor-derived alterations in ctDNA.
Types of mutations detected include SNV, Indel.
Ability to evaluate ctDNA at ultra-low variant allele frequencies.
Retrieves more unique reads than traditional duplication and deletion algorithms, reducing sequencing costs.

Specimen requirements of our ctDNA panel

Specimen: Plasma (> 20 ng of cfDNA)

Volume: 5 mL blood.

Collection: Blood is collected by routine phlebotomy.

Container: Lavender-top (EDTA) tube or yellow-top (ACD) tube.

Ready-to-use CDCAP NGS Panel Workflow

CD Genomics provides accurate and cost-effective panel sequencing and bioinformatics analysis of colorectal, breast and lung cancers ctDNA. Our dedicated team of experts performs quality management, following every procedure to ensure confident and unbiased results. The general workflow for ctDNA panel is outlined below.

ctDNA NGS Panel for Liquid Biopsy Research

Our experts are dedicated to pioneering research on ctDNA. Our custom ctDNA panel is designed to use ctDNA as a liquid biopsy to improve the current tumor diagnostic system and enable accurate determination of tumor progression, prognosis, and aid in targeted therapy. We look forward to working with you on your innovative discoveries, so please do not hesitate to contact us.

Reference

Cheng F, et al. (2016) Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget. 7(30):48832-48841.

* For Research Use Only. Not for use in diagnostic procedures.